BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018;2018. [PMID: 30148248 DOI: 10.1200/po.17.00235] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Menon AA, Deshpande V, Suster D. MDM2 for the practicing pathologist: a primer. J Clin Pathol 2023:jcp-2022-208687. [PMID: 36898827 DOI: 10.1136/jcp-2022-208687] [Reference Citation Analysis]
2 Tsimberidou AM, Fountzilas E, Kurzrock R. Precision Medicine in Oncology Drug Development. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm052.pub3] [Reference Citation Analysis]
3 Bruzos AL, Santamarina M, García-souto D, Díaz S, Rocha S, Zamora J, Lee Y, Viña-feás A, Quail MA, Otero I, Pequeño-valtierra A, Temes J, Rodriguez-castro J, Villanueva A, Costas D, Rodríguez R, Prieto T, Tomás L, Alvariño P, Alonso J, Cao A, Iglesias D, Carballal MJ, Amaral AM, Balseiro P, Calado R, El Khalfi B, Izagirre U, de Montaudouin X, Pade NG, Probert I, Ricardo F, Ruiz P, Skazina M, Smolarz K, Pasantes JJ, Villalba A, Ning Z, Ju YS, Posada D, Demeulemeester J, Baez-ortega A, Tubio JMC. The evolution of two transmissible leukaemias colonizing the coasts of Europe.. [DOI: 10.1101/2022.08.06.503021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lieto E, Cardella F, Erario S, Del Sorbo G, Reginelli A, Galizia G, Urraro F, Panarese I, Auricchio A. Giant retroperitoneal liposarcoma treated with radical conservative surgery: A case report and review of literature. World J Clin Cases 2022; 10(19): 6636-6646 [DOI: 10.12998/wjcc.v10.i19.6636] [Reference Citation Analysis]
5 Volovat S, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. Pharmaceutics 2022;14:397. [DOI: 10.3390/pharmaceutics14020397] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Gu Y, He H, Wang M. Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer. Asia Pac J Oncol Nurs 2021;8:586-90. [PMID: 34527790 DOI: 10.4103/apjon.apjon-2142] [Reference Citation Analysis]
7 Wang S, Xie K, Liu T. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters. Front Immunol 2021;12:690112. [PMID: 34367148 DOI: 10.3389/fimmu.2021.690112] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
8 Sciot R. MDM2 Amplified Sarcomas: A Literature Review. Diagnostics (Basel) 2021;11:496. [PMID: 33799733 DOI: 10.3390/diagnostics11030496] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
9 Sivapiragasam A, Ashok Kumar P, Sokol ES, Albacker LA, Killian JK, Ramkissoon SH, Huang RSP, Severson EA, Brown CA, Danziger N, McGregor K, Ross JS. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Cancer Med 2021;10:53-61. [PMID: 33314633 DOI: 10.1002/cam4.3550] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
10 De Souza ALPB. Finding the hot spot: identifying immune sensitive gastrointestinal tumors. Transl Gastroenterol Hepatol 2020;5:48. [PMID: 33073043 DOI: 10.21037/tgh.2019.12.11] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Han XJ, Alu A, Xiao YN, Wei YQ, Wei XW. Hyperprogression: A novel response pattern under immunotherapy. Clin Transl Med 2020;10:e167. [PMID: 32997401 DOI: 10.1002/ctm2.167] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
12 Eskander RN, Elvin J, Gay L, Ross JS, Miller VA, Kurzrock R. Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. JCO Precis Oncol 2020;4:PO. [PMID: 33015532 DOI: 10.1200/PO.19.00248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Wang L, Hu Y, Wang S, Shen J, Wang X. Biomarkers of immunotherapy in non-small cell lung cancer. Oncol Lett 2020;20:139. [PMID: 32934707 DOI: 10.3892/ol.2020.11999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
14 Bai R, Chen N, Li L, Du N, Bai L, Lv Z, Tian H, Cui J. Mechanisms of Cancer Resistance to Immunotherapy. Front Oncol 2020;10:1290. [PMID: 32850400 DOI: 10.3389/fonc.2020.01290] [Cited by in Crossref: 65] [Cited by in F6Publishing: 76] [Article Influence: 21.7] [Reference Citation Analysis]
15 Denis M, Duruisseaux M, Brevet M, Dumontet C. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? Front Immunol 2020;11:492. [PMID: 32265935 DOI: 10.3389/fimmu.2020.00492] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
16 Forschner A, Hilke FJ, Bonzheim I, Gschwind A, Demidov G, Amaral T, Ossowski S, Riess O, Schroeder C, Martus P, Klumpp B, Gonzalez-Menendez I, Garbe C, Niessner H, Sinnberg T. MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. Cancers (Basel) 2020;12:E540. [PMID: 32110946 DOI: 10.3390/cancers12030540] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
17 Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology 2020;9:1708065. [PMID: 32117584 DOI: 10.1080/2162402X.2019.1708065] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
18 Hofman P. PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good! J Thorac Dis 2019;11:S396-8. [PMID: 30997230 DOI: 10.21037/jtd.2018.11.140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Sugimura H, Yoshimura K. Lymph node metastasis matters. J Thorac Dis 2019;11:S331-3. [PMID: 30997212 DOI: 10.21037/jtd.2018.12.127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Sapna G, Gokul S. Next generation sequencing in oral disease diagnostics. World J Stomatol 2018; 6(2): 6-10 [DOI: 10.5321/wjs.v6.i2.6] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]